NCT01081223View on ClinicalTrials.gov

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

GliomaHigh Grade AstrocytomaGlioblastoma Multiforme

Interventions

BIOLOGICAL

Cancer vaccine plus immune adjuvant

Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.

Trial Locations (1)

64111

Saint Luke's Hospital, Kansas City